Predominant Mutations of SARS-CoV-2: Their Geographical Distribution and Potential Consequences

dc.contributor.authorUnlu, Sezin
dc.contributor.authorUskudar Guclu, Aylin
dc.contributor.authorBasustaoglu, Ahmet
dc.contributor.orcID0000-0001-7490-7981en_US
dc.contributor.orcID0000-0002-1872-028Xen_US
dc.contributor.researcherIDAAQ-4702-2021en_US
dc.contributor.researcherIDAAU-6196-2020en_US
dc.date.accessioned2022-09-13T08:23:55Z
dc.date.available2022-09-13T08:23:55Z
dc.date.issued2021
dc.description.abstractSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged in late December 2019 in Wuhan, China. More than 83 million people have been infected, and more than 1.8 million people have died, as reported to the World Health Organization on the 3rd of January, 2021. Analysis of genetic variations is critical for understanding the spreading pattern of SARS-CoV-2 across several countries. This review aimed to gather information about the prominent mutations of SARS-CoV-2 by analyzing the origin, viral pathogenesis, and mutation rate. Moreover, we concluded their potential impacts on SARS-CoV-2 therapeutics. Mutations in the spike protein (D614G, N501Y, E484K, A222V, S477N, and G485R), ORF1ab (P323L, N628N, Y455Y, A97V, and F106F), nucleocapsid protein (R203K and G204R), ORF8 (L84S), and ORF3a (Q57H and G251V) were examined in this review by analyzing relevant articles from the beginning of the current pandemic to the most recent date. A detailed analysis of articles demonstrates that D614G is the major variation distributed globally, and its frequency increased rapidly from early in March, followed by several other variations in either spike or different proteins. In addition, it was seen that the currently circulating N501Y and E484K variants revealed a public concern regarding vaccines' efficacy. Investigation of variations of SARS-CoV-2 would lead to understanding their potential mechanism of action against SARS-CoV-2, thereby suggesting suitable therapeutics. Several mechanisms were suggested to have a role in SARS-CoV-2 mutation rate and evolution. Possible therapeutics and vaccines against SARS-CoV-2 were proposed.en_US
dc.identifier.endpage12en_US
dc.identifier.issn2147-673Xen_US
dc.identifier.scopus2-s2.0-85111541838&en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://mjima.org/uploads/pdf/pdf_232.pdf
dc.identifier.urihttp://hdl.handle.net/11727/7708
dc.identifier.volume10en_US
dc.identifier.wos000639333200001en_US
dc.language.isoengen_US
dc.relation.isversionof10.4274/mjima.galenos.2021.2021.15en_US
dc.relation.journalMEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2en_US
dc.subjectgenomic variationsen_US
dc.subjectimpacts of SARS-CoV-2 mutationsen_US
dc.subjectgeographical distributionen_US
dc.titlePredominant Mutations of SARS-CoV-2: Their Geographical Distribution and Potential Consequencesen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ds127.pdf
Size:
794.79 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: